HomeCompareRLFTD vs MCD

RLFTD vs MCD: Dividend Comparison 2026

RLFTD yields 49.02% · MCD yields 2.35%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RLFTD wins by $296.0K in total portfolio value
10 years
RLFTD
RLFTD
● Live price
49.02%
Share price
$4.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$374.5K
Annual income
$74,708.98
Full RLFTD calculator →
MCD
McDonald's Corporation
● Live price
2.35%
Share price
$308.53
Annual div
$7.26
5Y div CAGR
42.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78.5K
Annual income
$26,227.70
Full MCD calculator →

Portfolio growth — RLFTD vs MCD

📍 RLFTD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLFTDMCD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLFTD + MCD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLFTD pays
MCD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD
Annual income on $10K today (after 15% tax)
$4,166.67/yr
After 10yr DRIP, annual income (after tax)
$63,502.63/yr
MCD
Annual income on $10K today (after 15% tax)
$200.01/yr
After 10yr DRIP, annual income (after tax)
$22,293.55/yr
At 15% tax rate, RLFTD beats the other by $41,209.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + MCD for your $10,000?

RLFTD: 50%MCD: 50%
100% MCD50/50100% RLFTD
Portfolio after 10yr
$226.5K
Annual income
$50,468.34/yr
Blended yield
22.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCD right now

RLFTD
No analyst data
Altman Z
-12.4
Piotroski
5/9
MCD
Analyst Ratings
37
Buy
23
Hold
1
Sell
Consensus: Buy
Price Target
$351.76
+14.0% upside vs current
Range: $320.00 — $385.00
Altman Z
4.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys
0
MCD buys
0
No recent congressional trades found for RLFTD or MCD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLFTDMCD
Forward yield49.02%2.35%
Annual dividend / share$2.00$7.26
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%42.3%
Portfolio after 10y$374.5K$78.5K
Annual income after 10y$74,708.98$26,227.70
Total dividends collected$297.4K$58.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: RLFTD vs MCD ($10,000, DRIP)

YearRLFTD PortfolioRLFTD Income/yrMCD PortfolioMCD Income/yrGap
1← crossover$15,602$4,901.96$10,815$334.85+$4.8KRLFTD
2$23,842$7,147.68$11,826$491.71+$12.0KRLFTD
3$35,719$10,208.01$13,123$730.06+$22.6KRLFTD
4$52,512$14,292.70$14,853$1,100.07+$37.7KRLFTD
5$75,825$19,637.72$17,257$1,690.61+$58.6KRLFTD
6$107,634$26,501.16$20,752$2,667.01+$86.9KRLFTD
7$150,326$35,157.45$26,103$4,354.83+$124.2KRLFTD
8$206,739$45,889.95$34,794$7,437.78+$171.9KRLFTD
9$280,193$58,982.29$49,926$13,461.60+$230.3KRLFTD
10$374,515$74,708.98$78,550$26,227.70+$296.0KRLFTD

RLFTD vs MCD: Complete Analysis 2026

RLFTDStock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

MCDConsumer Discretionary

McDonald's Corporation operates and franchises McDonald's restaurants in the United States and internationally. Its restaurants offer hamburgers and cheeseburgers, chicken sandwiches and nuggets, wraps, fries, salads, oatmeal, shakes, desserts, sundaes, soft serve cones, bakery items, soft drinks, coffee, and beverages and other beverages, as well as breakfast menu, including biscuit and bagel sandwiches, breakfast burritos, hotcakes, and other sandwiches. As of December 31, 2021, the company operated 40,031 restaurants. McDonald's Corporation was founded in 1940 and is headquartered in Chicago, Illinois.

Full MCD Calculator →
📬

Get this RLFTD vs MCD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHDRLFTD vs JEPIRLFTD vs ORLFTD vs KORLFTD vs MAINRLFTD vs YUMRLFTD vs QSRRLFTD vs SBUX

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.